Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more

Lung cancer is the leading cause of death in both men and women in the United States (1). With increasing implementation of low dose computed tomography (CT) screening in high-risk populations, more patients should be diagnosed with early stage disease in the coming years, amenable to curative intent therapy (2). However, no firm consensus yet guides the frequency and modality of surveillance imaging following definitive treatment, with variable guidelines from large national and international oncologic societies.